期刊文献+

定量检测乙型肝炎患者血清HBeAg/HBeAb与HBV-DNA之间相关性及临床意义 被引量:4

暂未订购
导出
摘要 目的探讨时间分辩免疫荧光(TRFIA)定量测定HBeAg/HbeAb和HBV-DNA含量之间的相关性,为临床诊疗提供依据。方法筛选e系统阳性乙肝病人570份,同日测定其HBV-DNA含量,进行HbeAg或HbeAb与HBV-DNA水平的相关性分析。结果HBeAg的含量(NCU/ml)与HBV-DNA的含量(拷贝/ml)成正相关(γ=0.575),在HBV-DNA103~107拷贝/ml之间时,HBV-DNA的阳性率比HBeAg高(P<0.001),在HBV-DNA大于107拷贝/ml时,HBV-DNA的阳性率与HBeAg相比无显著性差异(P>0.05);HBV-DNA在103~105拷贝/ml之间时,HBeAb有较高的阳性率,并随着HBV-DNA的含量增加而逐渐下降,HBeAb的含量(NCU/ml)与HBV-DNA的含量(拷贝/ml)成负相关(γ=-0.25)。结论TRFIA定量测定血清HBeAg/HBeAb与HBV-DNA复制水平具有良好相关性。HBeAg/HBeAb血清转换是HBV复制下降的较可靠标志。
机构地区 南昌市第九医院
出处 《实验与检验医学》 CAS 2008年第5期525-527,共3页 Experimental and Laboratory Medicine
  • 相关文献

参考文献8

二级参考文献32

  • 1朱江 张树木.HBV感染血清HBeAb/IC和HBV—DNA间接的关系[J].中华肝病杂志,2000,8(2):932-932.
  • 2Zhang XX, Liu CM, Gong QM, et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterolo Hepatolo, 2003, 1353-1357.
  • 3Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut, 2000, 46: 562-568.
  • 4Maria Buti, Rafael Esteban. Entecavir, FTC, L-RMAU, LdT and others. J Hepatol, 2003, 39: S139-S142.
  • 5Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 2002, 37: 259-265
  • 6Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18: 239-245.
  • 7The EASL Jury. EASL international consensus conference on hepatitis B. J Hepatol, 2003, 38: 533-540.
  • 8Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2001, 34: 1225-1241.
  • 9Li LL, Chun TW, Yin ML, et al. Prophylactic lamivudine prevents hepatitis B reactivation and mortality in patients receiving immunosuppression and chemotherapy. Hepatology, 2000, 32(Pt 2): 1183.
  • 10Liaw YF, Sung JJY, Chow WC, et al. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blined placebo-controlled clinical trial. Hepatology, 2003, 38(Suppl)1: 262A.

共引文献14264

同被引文献51

引证文献4

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部